Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

ignificant improvement in skin lesions including facial angiofibromas was observed, which can be a key concern for people living with TSC."  

Everolimus targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(8). Tuberous sclerosis complex is caused by defects in the TSC1 and/or TSC2 genes(9). When these genes are defective, mTOR activity is increased, which can cause uncontrolled tumor cell growth and proliferation, blood vessel growth and altered cellular metabolism(2,9). By inhibiting mTOR activity in this signaling pathway, everolimus may reduce cell proliferation and blood vessel growth related to angiomyolipoma associated with TSC(2,8,9).

"The positive findings seen in this trial coupled with the known efficacy of everolimus in patients with SEGA point to the important role of mTOR inhibition with everolimus in treating these manifestations of TSC," said Herve Hoppenot, President, Novartis Oncology. "The outcomes support our further research efforts evaluating everolimus as a treatment option across the various conditions associated with TSC."

Affecting approximately 25,000 to 40,000 people in the US and one to two million people worldwide, TSC is associated with a variety of resulting disorders including skin lesions, seizures, swelling in the brain (hydrocephalus) and developmental delays(3,9).

About EXIST-2 EXIST-2 is a prospective, double-blind, randomized, parallel group, placebo-controlled, international, multicenter Phase III study of everolimus versus placebo for the treatment of patients with angiomyolipoma associated with TSC(1,10). Trial patients (median age=31, range 18-61) were randomized 2:1 to receive either everolimus (n=79) or placebo (n=39) at a daily starting dose of 10 mg. By the cut-off of June 30, 2011, the median treatment duration in the double-blind period was 38.1 weeks (range 2-105 weeks) in the everolimus arm and 3
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014  In the Friday, December 19 edition of ... to Healthcare Information Technology (HIT) features Konica Minolta, the company announced ... partnership with several leading healthcare organizations. In addition ... metropolitan markets, such as New York , ... Baltimore , Minneapolis and ...
(Date:12/19/2014)... -- TODAY, AEGATE, the leader in medicine ... appointment of Peter Fox as Chief Technology ... Partner Officer. Peter has served as Development ... by Oracle in 2011. Prior to Datanomic, ... and subsequently Convergys, a world renowned billing system ...
(Date:12/19/2014)...  Newport Corporation (NASDAQ: NEWP ) ... the company,s Board of Directors.  Dr. Kadia is ... of Evans Analytical Group, a leading global provider ... to companies in a wide range of industries.   ... Group, Dr. Kadia spent nine years with Life ...
Breaking Medicine Technology:USA Today Supplement Featuring Konica Minolta Focuses on Impact of Healthcare IT 2Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
(Date:12/19/2014)... Silver Dollar City is picking ... for the first time ever, Silver Dollar City has a ... Records 2015, listing the park’s wood coaster Outlaw Run as ... awards announced this week, Silver Dollar City is named in ... US,” USA Today’s 10Best awards for “Best Public Lights Display,” ...
(Date:12/19/2014)... The Medspa at Hendrick in Abilene, ... respected cosmetic brand Juvéderm. Voluma XC treats volume loss ... Medspa at Hendrick is pleased to be able to ... to its clients. , Voluma is the first and ... treat the mid-face and cheek area. This non-invasive treatment ...
(Date:12/19/2014)... News) -- Potentially illness-causing E. coli bacteria were found ... according to a new study. Researchers checked cilantro, ... farmers markets in Los Angeles and Orange counties in ... 150 samples tested, 24 percent were positive for E. ... the researchers. Both types of bacteria can cause ...
(Date:12/19/2014)... NC (PRWEB) December 19, 2014 Surviving Mesothelioma ... and EPA information indicates that these pipes can leach asbestos ... go to the full story on the Surviving Mesothelioma ... the erosion of natural asbestos deposits, decaying water mains made ... drinking water. , To protect consumers from mesothelioma ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Silver Dollar City Nets New Titles: Guinness Book of World Records, Plus CNN Travel, USA Today & Fodor’s Top Places for Christmas Lights 2Health News:Breakthrough New Injectable Dermal Filler Voluma XC Offered by The MedSpa at Hendrick 2Health News:E. Coli Germs Found on Farmers Market Herbs 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2
... March 25 MarketResearch.com, the leading,distributor of ... a,business partnership with Steinkrug Publications which allows ... market analyses,through the MarketResearch.com website., The ... access to complete product descriptions and tables ...
... by Novel Emerging Therapies, Including Drugs from Arena ... Resources, WALTHAM, Mass., March 25 Decision Resources, ... pharmaceutical and,healthcare issues, finds that the obesity drug market ... Kingdom and Japan will experience,more than five-fold growth, rising ...
... Famed ,Father of Aerobics, Dr. Kenneth Cooper Credited with ... to Children, DALLAS, March 25 Aerobics. For ... forms of exercise from the jogging,craze to dancing in ... one man, aerobics was a journey to define physical ...
... Calif., March 25 Ingenuity Systems, the,leading ... researchers,today announced it has achieved key milestones ... (CRADA) with the Food and Drug,Administration. Significant ... the curation of new biomarker and toxicology ...
... LEHIGH VALLEY, Pa., March 25 Spring has ... preparing for warmer days and,wearing lighter, figure revealing ... Tammy Lakatos-Shames and Lyssie,Lakatos, RD, LD, CDN, CPT, ... in overall wellness., Whether trying to lose ...
... fewer symptoms of anxiety or depression, while children with ... difficulties forming relationships and being accepted by friends. However, ... depression lead to the social problems, or vice versa. ... to contribute to anxiety and depression than the reverse. ...
Cached Medicine News:Health News:MarketResearch.com Announces Distribution of CarbonFree Research 2Health News:Drug Treatment Market For Obesity Will Increase More Than Five-Fold, Reaching $2.7 Billion in 2016 2Health News:Aerobics Celebrates 40th Anniversary 2Health News:Ingenuity Systems Delivers Key Milestones in FDA Collaboration to Facilitate Genomic Data Review 2Health News:Nutrition Made Simple: Organizing Wellness for Warmer Days With DayTimers 2Health News:Youth's social problems contribute to anxiety and depression 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: